The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram
Abstract
Background Escitalopram is a dual serotonin reuptake inhibitor (SSRI) approved for the treatment of depression and anxiety disorders. It is the S-enantiomer of citalopram, and is responsible for the serotonin reuptake activity, and thus for its pharmacological effects. Previous studies pointed out that clinically efficacious doses of other SSRIs produce an occupancy of the serotonin reuptake transporter (SERT) of about 80% or more. The novel radioligand [123I]ADAM and single photon emission computer tomography (SPECT) were used to measure midbrain SERT occupancies for different doses of escitalopram and citalopram.Methods Twenty-five healthy subjects received a single dose of escitalopram [5 mg (n=5), 10 mg (n=5), and 20 mg (n=5)] or citalopram [(10 mg (n=5) and 20 mg (n=5)]. Midbrain SERT binding was measured with [(123)I]ADAM and SPECT on two study days, once without study drug and once 6 h after single dose administration of the study drug. The ratio of midbrain-cerebellum/cerebellum was the outcome measure (V3") for specific binding to SERT in midbrain. Subsequently, SERT occupancy levels were calculated using the untreated baseline level for each subject. An Emax model was used to describe the relationship between S-citalopram concentrations and SERT occupancy values. Additionally, four subjects received placebo to determine test-retest variability.Results Single doses of 5, 10, or 20 mg escitalopram led to a mean SERT occupancy of 60+/-6, 64+/-6, and 75+/-5%, respectively. SERT occupancies for subjects treated with single doses of 10 and 20 mg citalopram were 65+/-10 and 70+/-6%, respectively. A statistically significant difference was found between SERT occupancies after application of 10 and 20 mg escitalopram, but not for 10 and 20 mg citalopram. There was no statistically significant difference between the SERT occupancies of either 10 mg citalopram or 10 mg escitalopram, or between 20 mg citalopram and 20 mg escitalopram. Emax was slightly higher after administration of citalopram (84%) than escitalopram (79%). In the test-retest study, a mean SERT "occupancy" of 4% was found after administration of placebo, the intraclass correlation coefficient was 0.92, and the repeatability coefficient was 0.25.Conclusion SPECT and [123I]ADAM were used to investigate SERT occupancies after single doses of escitalopram or citalopram. The test-retest study revealed good reproducibility of SERT quantification. Similar SERT occupancies were found after administration of equal doses (in respect to mg) of escitalopram and citalopram, giving indirect evidence for a fractional blockade of SERT by the inactive R-citalopram.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a total of 16 articles (reporting on 17 unique studies) were included [17–19, 28–40].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [18]
Citations
Cites
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 3×
“Furthermore, they found a significant relationship between SERT occupancy and serum concentration after administration of citalopram ( Meyer et al. 2004 ), which was not observed in the present study.”
BackgroundResultInfluentialReduced Serotonin Type 1AReceptor Binding in Panic Disorder: Figure 1.
Neumeister, A., Bain, E., Nugent, A. C., Carson, R. E., Bonne, O., Luckenbaugh, D. A., Eckelman, W., Herscovitch, P., Charney, D. S., & Drevets, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4921-03.2004 · Cited by 355
Laruelle, M., Baldwin, R. M., Malison, R. T., Zea‐Ponce, Y., Zoghbi, S. S., Al‐Tikeriti, M. S., Sybirska, E. H., Zimmermann, R. C., Wisniewski, G., Neumeyer, J. L., et al. (1993) · Synapse · doi:10.1002/syn.890130402 · Cited by 351
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Dysfunctional Attitudes and 5-HT2 Receptors During Depression and Self-Harm
Meyer, J. H., McMain, S., Kennedy, S. H., Korman, L., Brown, G. M., DaSilva, J. N., Wilson, A. A., Blak, T., Eynan-Harvey, R., Goulding, V. S., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.90 · Cited by 264
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Escitalopram versus citalopram: the surprising role of the R-enantiomer
S�nchez, C., B�ges�, K., Ebert, B., Reines, E., & Braestrup, C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1865-z · Cited by 248
Moore, N., Verdoux, H., & Fantino, B. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00002 · Cited by 188
Willeit, M., Praschak-Rieder, N., Neumeister, A., Pirker, W., Asenbaum, S., Vitouch, O., Tauscher, J., Hilger, E., Stastny, J., Brücke, T., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00293-0 · Cited by 179
Self-citationMontgomery, S. A., Loft, H., Sanchez, C., Reines, E. H., & Papp, M. (2001) · Pharmacology and Toxicology · doi:10.1034/j.1600-0773.2001.d01-118.x · Cited by 174
Gorman, J. M., Korotzer, A., & Su, G. (2002) · CNS Spectrums · doi:10.1017/s1092852900028595 · Cited by 169
Mørk, A., Kreilgaard, M., & Sánchez, C. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00138-2 · Cited by 163
High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue
Ba¨ckstro¨m, I., Bergstro¨m, M., & Marcusson, J. (1989) · Brain Research · doi:10.1016/0006-8993(89)90511-8 · Cited by 162
Oya, S., Choi, S.-R., Hou, C., Mu, M., Kung, M.-P., Acton, P. D., Siciliano, M., & Kung, H. F. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00084-6 · Cited by 158
Significant dissociation of brain and plasma kinetics with antipsychotics
Tauscher, J. T., Jones, C. E., Remington, G. J., Zipursky, R. B., & Kapur, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001009 · Cited by 155
Self-citationChen, F., Larsen, M. B., Sánchez, C., & Wiborg, O. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.08.008 · Cited by 151
SSRIs and SNRIs: broad spectrum of efficacy beyond major depression.
Gorman, J. M., & KENT, J. M. (1999) · PubMed · Cited by 129
?-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo
Pirker, W., Asenbaum, S., Kasper, S. F., Walter, H., Angelberger, P., Koch, G., Pozzera, A., Deecke, L., Podreka, I., & Br�cke, T. (1995) · Journal of Neural Transmission · doi:10.1007/bf01276462 · Cited by 127
Self-citationOnset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
Self-citationKasper, S. F., Tauscher, J. T., Willeit, M., Stamenkovic, M., Neumeister, A., Kufferle, B., Barnas, C., Stastny, J., Praschak-Rieder, N., Pezawas, L., et al. (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150614 · Cited by 90
Self-citationSánchez, C., Gruca, P., & Papp, M. (2003) · PubMed · doi:10.1097/01.fbp.0000087733.21047.60 · Cited by 89
Quantification of serotonin transporters in nonhuman primates using [(123)I]ADAM and SPECT.
Acton, P. D., Choi, S.-R., Hou, C., Plößl, K., & Kung, H. F. (2001) · PubMed · Cited by 85
Selective in vitro and in vivo binding of [125I]ADAM to serotonin transporters in rat brain
Choi, S.-R., Hou, C., Oya, S., Mu, M., Kung, M., Siciliano, M., Acton, P. D., & Kung, H. F. (2000) · Synapse · doi:10.1002/1098-2396(20001215)38:4<403::aid-syn5>3.0.co;2-z · Cited by 82
Itoh, T., Saura, Y., Tsuda, Y., & Yamada, H. (1997) · Chirality · doi:10.1002/(sici)1520-636x(1997)9:7<686::aid-chir9>3.0.co;2-5 · Cited by 78
Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium
Rochat, B., Baumann, P., & Audus, K. L. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01461-4 · Cited by 77
Efficacy of escitalopram in patients with severe depression: a pooled analysis
Llorca, P., Azorin, J., Despiégel, N., & Verpillat, P. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2005.00440.x · Cited by 74
Stórustovu, S. Í., Sánchez, C., Pörzgen, P., Brennum, L. T., Larsen, A. K., Pulis, M., & Ebert, B. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705738 · Cited by 64
Frey, R. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00055-9 · Cited by 58
R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram
Sánchez, C., & Kreilgaard, M. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2003.12.001 · Cited by 57
In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment
Tauscher, J. T., Pirker, W., de Zwaan, M., Asenbaum, S., Brücke, T., & Kasper, S. F. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00013-3 · Cited by 56
Self-citationKauppinen, T., Bergström, K., Heikman, P. K., Hiltunen, J. O., & Ahonen, A. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1027-7 · Cited by 56
Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study
Erlandsson, K., Sivananthan, T., Lui, D., Spezzi, A., Townsend, C., Mu, S., Lucas, R., Warrington, S., & Ell, P. J. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1912-y · Cited by 54
Sánchez, C., Gruca, P., Bień, E., & Papp, M. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00165-5 · Cited by 53
Catafau, A. M., Pérez, V., Penengo, M. M., Bullich, S., Danùs, M., Puigdemont, D., Pascual, J. C., Corripio, I., Llop, J., Perich, J., et al. (2005) · PubMed · Cited by 50
The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects
Malling, D., Poulsen, M. N., & Søgaard, B. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02423.x · Cited by 41
Kasper, S. F., Vieira, A., Schmidt, R., & Richter, P. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014487 · Cited by 29
Self-citationStereoselective single‐dose kinetics of citalopram and its metabolites in rats
Kugelberg, F. C., Björn Carlsson, A., Ahlner, J., & Bengtsson, F. (2003) · Chirality · doi:10.1002/chir.10266 · Cited by 29
Larsen, A. K., Brennum, L. T., Egebjerg, J., Sánchez, C., Halldin, C., & Andersen, P. H. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705693 · Cited by 28
Lack of Citalopram Effect on Oral Digoxin Pharmacokinetics
Larsen, F., Priskorn, M., & Overø, K. F. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010041 · Cited by 24
Do SSRIs differ in their antidepressant efficacy
Kasper, S. F., & Heiden, A. M. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100905 · Cited by 21
Self-citationUnique mechanism of action for escitalopram: does it hold the promise?
Kasper, S. F. (2004) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500410005504 · Cited by 7
Self-citationEvaluation of the serotonin transporter ligand [123I]ADAM for SPECT studies in humans
Frøkjær, V. G., Pinborg, L. H., Madsen, J., & Knudsen, G. M. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9591524.0651 · Cited by 3
Healy, D. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100219 · Cited by 3
Research works printed but not linked: 4
- Alexopoulos GS, Privitera W, Ventura D, Bose A, Lenz SM, Wang Q (2004) Fixed dose of escitalopram (10 mg/day) and a flexible dosing regime of sertraline (50–200 mg/day) in a randomized, double-blind comparison in depressed patients. World J Biol Psychiatry 5(Suppl 1):97
- Baumann P, Larsen F (1995) The pharmacokinetics of citalopram. Rev Contemp Pharmacother 6:287–295
- Klein N, Sacher J, Mossaheb N, Asenbaum S, Pötzi C, Dobrozemsky G, Dudczak R, Kasper S, Tauscher J (2004) Quantification of serotonin transporters with [123I]ADAM and SPECT in healthy human subjects: preliminary data on tracer kinetics. Biol Psychiatry 55:S212
- Sacher J, Asenbaum S, Klein N, Geiss-Granadia T, Mossaheb N, Pötzi C, Attarbaschi T, Lanzenberger R, Dudczak R, Kasper S, Tauscher J (2006) [123I]ADAM: a novel SPECT ligand for quantification of serotonin transporters in humans. Int J Neuropsychopharmacology (in press)
Cited by
5‐HT radioligands for human brain imaging with PET and SPECT
Paterson, L. M., Kornum, B. R., Nutt, D. J., Pike, V. W., & Knudsen, G. M. (2011) · Medicinal Research Reviews · doi:10.1002/med.20245 · Cited by 159
Herrmann, N., Black, S. E., Chow, T. W., Cappell, J., Tang‐Wai, D. F., & Lanctôt, K. L. (2011) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31823033f3 · Cited by 146
Windischberger, C., Lanzenberger, R., Holik, A., Spindelegger, C., Stein, P., Moser, U., Gerstl, F., Fink, M., Moser, E., & Kasper, S. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.013 · Cited by 114
Self-citationImproving response inhibition systems in frontotemporal dementia with citalopram
Hughes, L. E., Rittman, T., Regenthal, R., Robbins, T. W., & Rowe, J. B. (2015) · Brain · doi:10.1093/brain/awv133 · Cited by 100
“Second, is to identify pharmacological targets for treatment based on the psychopharmacology of re- sponse inhibition and the neurotransmitter deficits in bvFTD.”
BackgroundBonaventure, P., Dugovic, C., Kramer, M. L., Boer, P. D., Singh, J. B., Wilson, S. J., Bertelsen, K. M., Di, J., Shelton, J. E., Aluisio, L. E., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193995 · Cited by 90
“Investigations of the 5-HT transporter occupancy by using positron emission tomography have demonstrated an average 5-HT transporter occupancy after a single dose of 20 mg of citalopram of 70%, whereas 20 mg of escitalopram led to a 5-HT transporter occupancy of 75% (Klein et al., 2006).”
Metadata
- Authors
- Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., Dudczak, R., Tauscher, J., & Kasper, S.
- Affiliations
- University of Vienna (AT)
- Medical University of Vienna (AT)
- Corresponding author
- Kasper, S.
- Venue
- Psychopharmacology
- Published
- 2006-09-06
- Volume
- 188
- Issue
- 3
- Pages
- 263-272
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2035444856
- Cited by
- 77
- References
- 44
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 1 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 2 · 2012: 3
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- H. Lundbeck A/S
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- escitalopram, citalopram, midbrain, dose-response relationship, Emax model, serotonin reuptake inhibitors, radioligand binding, healthy volunteers, test-retest variability, pharmacodynamic imaging, depression treatment, anxiety disorder treatment
- MeSH terms
- Administration, Oral, Adult, Cerebellum, Cinanserin, Dose-Response Relationship, Drug, Humans, Iodine Radioisotopes, Male, Mesencephalon, Metabolic Clearance Rate, Nausea, Protein Binding, Sleep Wake Disorders, Stereoisomerism, Time Factors, Xerostomia, Citalopram, Tomography, Emission-Computed, Single-Photon, Akathisia, Drug-Induced, Selective Serotonin Reuptake Inhibitors, Area Under Curve, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.